328 related articles for article (PubMed ID: 10949982)
1. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia.
Sidi V; Roilides E; Bibashi E; Gompakis N; Tsakiri A; Koliouskas D
J Chemother; 2000 Aug; 12(4):326-31. PubMed ID: 10949982
[TBL] [Abstract][Full Text] [Related]
2. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
3. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with hematological malignancies: microbiological, clinical and economic evaluation.
D'Antonio D; Staniscia T; Piccolomini R; Fioritoni G; Rotolo S; Parruti G; Di Bonaventura G; Manna A; Savini V; Fiorilli MP; Di Giovanni P; Francione A; Schioppa F; Romano F
Chemotherapy; 2004 Jun; 50(2):81-7. PubMed ID: 15211082
[TBL] [Abstract][Full Text] [Related]
4. The role of teicoplanin in the treatment of febrile neutropenia.
Menichetti F
J Chemother; 2000 Nov; 12 Suppl 5():34-9. PubMed ID: 11131962
[TBL] [Abstract][Full Text] [Related]
5. Tolerability of teicoplanin in 117 hospitalized adults with previous vancomycin-induced fever, rash, or neutropenia: a retrospective chart review.
Hung YP; Lee NY; Chang CM; Lee HC; Wu CJ; Chen PL; Lee CC; Chung CH; Ko WC
Clin Ther; 2009 Sep; 31(9):1977-86. PubMed ID: 19843487
[TBL] [Abstract][Full Text] [Related]
6. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer.
Rolston KV; Nguyen H; Amos G; Elting L; Fainstein V; Bodey GP
J Infect Dis; 1994 Feb; 169(2):350-5. PubMed ID: 8106768
[TBL] [Abstract][Full Text] [Related]
8. A closer look at vancomycin, teicoplanin, and antimicrobial resistance.
Zeckel ML
J Chemother; 1997 Oct; 9(5):311-31; discussion 332-5. PubMed ID: 9373787
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin-induced neutropenia resolves after substitution with teicoplanin.
Sanche SE; Dust WN; Shevchuk YM
Clin Infect Dis; 2000 Sep; 31(3):824-5. PubMed ID: 11017842
[TBL] [Abstract][Full Text] [Related]
10. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
11. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
Chow AW; Jewesson PJ; Kureishi A; Phillips GL
Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
[TBL] [Abstract][Full Text] [Related]
12. Glycopeptide-induced vasculitis--cross-reactivity between vancomycin and teicoplanin.
Marshall C; Street A; Galbraith K
J Infect; 1998 Jul; 37(1):82-3. PubMed ID: 9733391
[TBL] [Abstract][Full Text] [Related]
13. Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.
Chaftari AM; Hachem R; Jordan M; Garoge K; Al Hamal Z; El Zakhem A; Viola GM; Granwehr B; Mulanovich V; Gagel A; Reitzel R; Yousif A; Jiang Y; Raad I
Antimicrob Agents Chemother; 2016 Jan; 60(1):239-44. PubMed ID: 26482312
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.
Kato-Hayashi H; Niwa T; Ohata K; Harada S; Matsumoto T; Kitagawa J; Tsurumi H; Suzuki A
J Clin Pharm Ther; 2019 Dec; 44(6):888-894. PubMed ID: 31373043
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin in the treatment of serious infection.
Schaison G; Graninger W; Bouza E
J Chemother; 2000 Nov; 12 Suppl 5():26-33. PubMed ID: 11131961
[TBL] [Abstract][Full Text] [Related]
16. Enterococcus faecium sensitive to teicoplanin but not vancomycin.
Wilson AP; Felmingham D; Robbins M; Chopra R
J Hosp Infect; 1991 Aug; 18(4):322-4. PubMed ID: 1682372
[No Abstract] [Full Text] [Related]
17. Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin.
Rybak MJ; Bailey EM; Warbasse LH
Antimicrob Agents Chemother; 1992 Jun; 36(6):1204-7. PubMed ID: 1384423
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptide-induced neutropenia: cross-reactivity between vancomycin and teicoplanin.
Hsiao SH; Chang CM; Tsai JC; Lin CY; Liao LH; Lin WL; Wu TJ
Ann Pharmacother; 2007 May; 41(5):891-4. PubMed ID: 17426073
[TBL] [Abstract][Full Text] [Related]
19. Teicoplanin-induced hypersensitivity syndrome with a preceding vancomycin-induced neutropenia: a case report and literature review.
Hsiao SH; Chen HH; Chou CH; Lin WL; Liu Yeh PY; Wu TJ
J Clin Pharm Ther; 2010 Dec; 35(6):729-32. PubMed ID: 21054466
[TBL] [Abstract][Full Text] [Related]
20. Treatment of infective endocarditis caused by methicillin-resistant Staphylococcus aureus: teicoplanin versus vancomycin in a retrospective study.
Huang JH; Hsu RB
Scand J Infect Dis; 2008; 40(6-7):462-7. PubMed ID: 18584532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
